Searchable abstracts of presentations at key conferences in endocrinology

ea0089c38 | Clinical – Surgery/Applied Pathology | NANETS2022

Increased Incidence, Prevalence, and Surgical Management of Enteropancreatic Neuroendocrine Tumors Is Associated with Improvements in Survival - A Contemporary Analysis

Concors, MD Seth J , Tzeng, MD Ching-Wei D , Ikoma MD Naruhiko , Kim MD Michael , Cao, MD Hop Tran , Lee, MD Jeffery E , Katz, MD Matthew HG , Maxwell, MD, MBA Jessica E

Background: Neuroendocrine tumors (NETs) are increasing in incidence and prevalence. Small intestine, rectum, pancreas and appendix are the most common enteric sites of NETs, and when identified early, surgical resection can be curative. We hypothesized that observed increases in incidence and prevalence of NETs are primarily driven by earlier detection of loco-regional tumors. In turn, increases in incidence of early-stage tumors is associated with increases in resection and ...

ea0098b26 | Basic Science | NANETS2023

Cancer testis antigen and interleukin expression correlates with survival in small bowel neuroendocrine tumors

David Seo MD Y. , Witt MD, MAS Russell G. , Lazcano MD Rossana , MD Samuel Cass , Hudgens Courtney , Wani Khalida , Chelvanambi PhD Manoj , Johnson MS Sarah , Hernandez MD Sharia D. , Halperin MD Daniel M. , Lazar MD, PhD Alexander J. , Wargo MD, MMSc Jennifer A. , Estrella MD Jeannelyn S. , Maxwell MD, MBA Jessica E.

Background: Patients with small bowel neuroendocrine tumors (SBNETs) frequently present with metastatic disease, and unfortunately, the range and efficacy of available therapies is limited. Immunotherapeutic checkpoint inhibitors have demonstrated benefit in other malignancies and may also play a role in SBNETs, although relatively little is known about the immune infiltrate in these tumors. Toward a goal of developing novel immunomodulatory strategies, we sought to evaluate t...